The global wearable injectors market is likely to grow from $2,162.1 million in 2015 to $13.0 billion by 2024. With the explosive growth of bolus injectors and increasing interest of pharmaceutical companies in collaborating with device manufacturers for drug device combination, the market for wearable injectors is expected to show dramatic rise. The launch of bolus injector expands the usage of wearable injectors from diabetes to other disease segments, as the wearable injectors currently available in market are majorly insulin pumps. The growing need for continuous and subcutaneous drug delivery has developed the demand for wearable injectors among the patients.
Explore Report Sample at: http://bit.ly/2fdS4t1
As per the findings of the research, cancer is expected to be the largest application area of wearable injectors. According to the analyst, cancer and autoimmune disease are expected to be the major application areas for wearable injectors in the near future. The other key applications of wearable injectors include infectious disease, cardiovascular disease and blood disorders. Also, homecare is expected to be the largest end user of wearable injectors.
Growing need for advanced drug delivery is one of the major factors driving the growth of the global wearable injectors market. Increasing demand for homecare and advanced drug delivery requiring minimal expertise and lesser hospitalization of patients is expected to drive the demand for wearable injectors, globally. Also, many biopharmaceutical companies have been looking for a better mode of drug delivery for their portfolio of biologic drugs, for which wearable injectors are an appropriate solution.
Access Report Overview: http://bit.ly/2yYp3sD
The research states that the global wearable injectors market had a consolidated structure in 2015, where the top three competitors accounted for the major share in the global wearable injectors market. Some of the key players operating in the global market are Becton, Dickinson and Company, Medtronic plc, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Insulet Corporation, Unilife Corporation, CeQur SA, Enable Injections, ScPharmaceuticals, Inc., SteadyMed Ltd., Ypsomed Group, West Pharmaceutical Services, Inc. and Canè S.p.A.